Transplantation of EPCs overexpressing PDGFR-β promotes vascular repair in the early phase after vascular injury by Hang Wang et al.
RESEARCH ARTICLE Open Access
Transplantation of EPCs overexpressing
PDGFR-β promotes vascular repair in the
early phase after vascular injury
Hang Wang1†, Yang-Guang Yin2†, Hao Huang3, Xiao-Hui Zhao4, Jie Yu4, Qiang Wang4, Wei Li4, Ke-Yin Cai1
and Shi-Fang Ding5*
Abstract
Background: Endothelial progenitor cells (EPCs) play important roles in the regeneration of the vascular endothelial
cells (ECs). Platelet-derived growth factor receptor (PDGFR)-β is known to contribute to proliferation, migration, and
angiogenesis of EPCs, this study aims to investigate effects of transplantation of EPCs overexpressing PDGFR-β on
vascular regeneration.
Methods: We transplanted genetically modified EPCs overexpressing PDGFR-β into a mouse model with carotid
artery injury. After 3 days of EPCs transplantation, the enhanced green fluorescent protein (EGFP)-expressing cells
were found at the injury site and the lining of the lumen by laser scanning confocal microscope (LSCM). At 4, 7,
and 14 days of the carotid artery injury, reendothelialization was evaluated by Evans Blue staining. Neointima
formation was evaluated at day 14 with hematoxylin and eosin (HE) staining by calculating the neointimal area,
medial area, and neointimal/media (NI/M) ratio. Intimal cell apoptosis was evaluated using TUNEL assay. Then we
tested whether PDGF-BB-induced VSMC migration and PDGF-BB’s function in reducing VSMC apoptosis can be
attenuated by EPCs overexpressing PDGFR-β in a transwell co-culture system.
Results: Our results showed that EPCs overexpressing PDGFR-β accelerates reendothelialization and mitigates
neointimal formation at 14 days after injury. Moreover, we found that there is great possibility that EPCs overexpressing
PDGFR-β enhanc VSMC apoptosis and suppress VSMC migration by competitive consumption of PDGF-BB in the early
phase after carotid artery injury in mice.
Conclusions: We report the first in vivo and in vitro evidence that transplantation of genetically modified EPC can
have a combined effect of both amplifying the reendothelialization capacity of EPCs and inhibiting neointima formation
so as to facilitate better inhibition of adverse remodeling after vascular injury.
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Background
The normal arterial vessel wall is mostly composed of
endothelial cells (ECs), vascular smooth muscle cells
(VSMCs), and macrophages. Endothelial impairment is
believed to be a major contributor to atherosclerosis and
restenosis after percutaneous coronary intervention (PCI)
[1, 2]. Reendothelialization can effectively inhibit VSMC
migration and proliferation and decrease neointimal thick-
ening [3]. Therefore, acceleration of reendothelialization is
of special interest with regard to reducing neointima for-
mation to prevent postangioplasty restenosis and develop-
ment of atherosclerosis.
Endothelial progenitor cells (EPCs) include cells in
multiple stages from mother cells to mature ECs.
Both early EPCs that can repair the blood vessels and
the late EPCs that have strong proliferation ability are
involved in angiogenesis. Indeed, the numbers of
EPCs in a patient with atherosclerotic vascular dis-
ease, who needs endothelial repair, are much lower
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than that in a normal person [4–6]. Recently, several
studies showed that EPCs can be recruited to the
sites of endothelial injury, be differentiated into ma-
ture ECs, and can play important roles in reendotheli-
alization after vascular injury [7–10]. Platelet-derived
growth factor (PDGF) can enhance VSMC function
and injury-induced neointima formation. PDGF-BB
gene knockout mice show pathological defects such
as heart and blood vessel dilations, proving that
PDGF-BB plays a vital role in the establishment of
the circulatory system in the body [11]. Recently, it
was reported that PDGF-BB was locally produced by
injured arteries, and it contributed to the promotion
of migration, proliferation, and neointima formation
of local VSMCs for participation in vascular repair/
remodeling in human and animal vascular injury
models [12]. However, inhibition of PDGF-BB signal-
ing has been shown to reduce neointima formation
and inhibit vascular repair/remodeling after angio-
plasty [13–15]. Our previous study also showed that
overexpression of PDGF-receptor (PDGFR)-β pro-
moted PDGF-BB-induced proliferation, migration, and
angiogenesis of EPCs [16].
Based on known knowledge regarding PDGF-BB
and PDGFR-β on the biological functions of VSMCs
and EPCs, we propose that EPCs overexpressing
PDGFR-β may have effects on reendothelialization
during arterial repairment after injury. To test this,
we transplanted genetically modified EPCs overex-
pressing PDGFR-β into a mouse model with carotid
artery injury and evaluated whether locally released
PDGF-BB can stimulate homing of the transplanted
EPCs to the site of endothelial injury and improve
their biological functions. We further investigated
whether the homed EPCs overexpressing PDGFR-β
can compete for the locally produced PDGF-BB
produced by injured arteries with the VSMCs to
inhibit the local VSMC migration, proliferation, and
neointima formation. Our results showed that trans-
plantation of genetically modified EPC may have a
combined effect of both amplifying the reendotheliali-
zation capacity of EPCs for repairing injured arteries
as well as inhibiting the capacity of EPCs in neoin-
tima formation so as to facilitate better inhibition of
adverse remodeling after vascular injury.
Methods
Animals and protocols
All procedures were performed in compliance with the
Ethic Committee of Third Military Medical University
and the National Institute of Health Guide for the
Care and Use of Laboratory. Animals Male C57BL/6
mice (weight: 25–30 g, age: 6–8 weeks) were obtained
from the Laboratory Animal Center at the Third
Military Medical University (Chongqing, China). Mice
were firstly anaesthetized by 40 mg/kg sodium pento-
barbital (Sigma-Aldrich, St Lois, MO, USA) via iintra-
peritoneal (IP) injection. The extent of anaesthesia was
assessed by mouse’s reaction to the toe pinching
during the splenectomy or the carotid artery injury
surgery. Then they received 3 mg/kg ketorolac
tromethamine (Newtime, Shandong, China) by per
os(PO) to minimize the postoperative pain. At last all
mice were euthanized by IP injection of 240 mg/kg
sodium pentobarbital.
Splenectomy
Splenectomy was performed as described in our previ-
ous study [17]. Vessels of the mice were carefully ligated
using 6–0 silk ligatures via a lateral incision of the left
abdomen, followed by ablation of the spleen. The abdo-
men was immediately closed layer by layer with single
sutures using 6–0 silk. The mice were allowed to recover
for 14 days after which the carotid arterial injury was
induced.
EPC culturing and characterization
Culturing and characterization of mouse spleen-
derived EPCs was performed as described previously
[16, 18]. To determine the endothelial phenotype of
EPCs, the cells were incubated with 2.4 μg/mL
acLDL-DiI (Invitrogen, CA, USA) for 4 h, fixed with
4 % paraformaldehyde (PFA), and then incubated with
10 μg/mL FITC-UEA-1 (Sigma-Aldrich, St. Louis,
MO, USA) for 1 h. The cells positive for both
acLDL-DiI and UEA-1 were identified as differentiat-
ing EPCs. In addition, the phenotypes of EPCs were
evaluated by flow cytometry (FCM). Cells (1 × 106)
were incubated with the following monoclonal anti-
bodies: PE-conjugated anti-VEGFR-2 (eBiosciences,
San Diego, CA, USA), FITC-conjugated anti-Sca-1
(abCAM, Cambridge, MA, USA), or their correspond-
ing isotype controls (eBiosciences).
EPCs gene transfer
The plasmids pEGFP-N2 and pEGFP-N2-PDGFR-β
were kindly provided by Dr. Shangcheng Xu at the
Third Military Medical University. Transfection was
performed, as described previously [16], with the
Lipofectamine™ 2000 reagent (Invitrogen, Shanghai,
China), according to the manufacturer’s instruction.
The EPCs of the pEGFP-N2 or pEGFP-N2-PDGFR-β
groups were collected 24 h after transfection.
VSMC culturing and characterization
VSMCs were isolated from the thoracic aorta of mice
through explantation and cultured in Dulbecco’s
Modified Eagle Medium: nutrient mixture F-12
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(DMEM/F-12) culture medium (Gibco BRL, NY,
USA) supplemented with 20 % fetal calf serum (FCS,
Gibco BRL, NY, USA), 100 U/mL penicillin, and 100
U/mL streptomycin. Cells were kept at 37 °C in a 5 %
CO2 atmosphere. Cultures were confirmed by smooth
muscle α-actin (SMαA, NeoMarkers, CA, USA). Cells
from 3 to 6 passages were used for all experiments.
Carotid artery injury model and EPC transplantation
Injury of carotid artery was induced 14 days after
splenectomy, as described in our previous study [19].
Briefly, the bifurcation of the left carotid artery was
exposed through a midline incision on the ventral
side of the neck. A 6–0 silk slipknot was placed
around the common carotid artery and the internal
carotid artery to block their blood flow. Two ligatures
were placed proximally and distally around the exter-
nal carotid artery, and the distal ligature was then
tied off. A tailored hook made from a syringe (1 mL)
was used to place the silk around the external and
the internal carotid arteries. An incision was made
between the two ligatures to introduce the denuda-
tion device. The tailored flexible wire (0.014-in. diameter,
the tip of the wire was relatively thinner) was introduced
into the common carotid artery. The endothelium was de-
nuded by passing the wire back and forth through the ves-
sel three times. After removal of the wire, the proximal
ligature of the external carotid artery was tied off. The
slipknots were removed, and the blood flow was restored.
The skin incision was sutured with 6–0 silk. Then, the
mice were administered 200 μL saline alone or 200 μL
saline containing enhanced green fluorescent protein
(EGFP)-labeled EPCs (1 × 106) or EPCs overexpressing
PDGFR-β (1 × 106) via tail vein injection directly after
endothelial injury of the carotid artery and again after
24 h.
EPC tracing in vivo
To observe whether the transfected EPCs were cap-
able of homing to the site of injury, labeled pEGFP-
N2-EPCs and pEGFP-N2- PDGFR-β-EPCs (1 × 106)
were incubated with 2.4 μg/ml acLDL-DiI (Invitrogen,
CA, USA) for 1 h. Then the cells were washed with
PBS 3 times and injected into the mice’ tail vein in
200 μL saline after induction of arterial injury and
again after 24 h. 7 days later, EPC tracking and
immunohistochemistry were performed. Images of the
stained cells were obtained by a fluorescence micro-
scope (Leica).
RNA extraction and semi-quantitative reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from the arteries by using RNA-
out (Tianenze Biotech, Beijing, China), and the cDNA was
obtained through RT-PCR with the PrimeScript™ RT
Reagent Kit (Takara, Biotechnology, Dalian, China) by
using total RNA as a template, followed by amplification.
The primers used were as follows: PDGFR-β (sense) 5′-
CCGGCGCTGGCGAGTTAGTTT-3′, (antisense) 5′-
ACACCTACTTTTGAGGTCTCTGCAGG-3′; product
length 296 bp. PDGF-BB (sense) 5′-TGCTGAGCGAC-
CACTCCATC-3′, (antisense) 5′-TGTGCTCGGGTCAT
GTTCAAG-3′; product length 109 bp. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (sense) 5′- AAC
TTTGGCATTGTGGAAGGGCTC-3′, (antisense) 5′- AC
CCTGTTGCTGTAGCCGTATTCA-3′; product length
473 bp. All primers were obtained from Invitrogen
(Shanghai, China).
Western blotting
The protein concentration of tissue lysates was estimated
by the Bradford method, and the proteins were transferred
onto polyvinylidene fluoride (PVDF) membranes. The
membranes were blocked with 5 % non-fat milk, probed
with anti-PDGFR-β (Abcam, USA), anti-PDGF-BB (Santa
Cruz Biotechnology, USA), and anti-GAPDH (Cell
Signaling Biotechnology, Beverly, MA, USA), followed
by staining with horseradish peroxidase-coupled
secondary antibodies. The protein bands were visualized
by enhanced chemiluminescence (Amersham Pharmacia
Biotech, UK) and quantified by using the Quantity One
software (Bio-Rad, Hercules, USA).
Immunofluorescence
Before and 7 days after the carotid artery injury, the
carotid arteries were snap-frozen in liquid nitrogen in
optimal cutting temperature (OCT)-embedding medium
and stored at −80 °C. Six cross-sections were cut (5-μm
thickness) from the approximate middle portion of the
artery and used for the detection of PDGF-BB by
immunofluorescence. For fluorescence staining, the
sections were first incubated with an anti-PDGF-BB
primary mAb (1:100) and then with a FITC-labeled sec-
ondary antibody (Beyotime, Shanghai, China). Images of
the sections were obtained by a laser scanning confocal
microscope (LSCM; Leica).
Measurement of reendothelialization
After 4, 7, and 14 days of the carotid artery injury,
endothelial regeneration was evaluated by staining the
denuded areas by injecting 200 μL of 5 % Evans Blue
dye with saline via the tail vein into the heart. The
left common carotid artery was then harvested 5 mm
away from the carotid bifurcation. The reendothelia-
lized area appeared white in color (unstained),
whereas the non-endothelialized lesions appeared blue
(stained). The unstained-areas (in white) and the total
carotid artery areas were measured. The ratio of
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reendothelialized areas (unstained area) versus the
total carotid artery area were calculated.
Assessment of neointimal and medial areas
For histological analysis, hematoxylin and eosin (HE)
staining was performed, according to the standard
protocols; three sections taken from the middle por-
tion of each artery, 14 days after the carotid artery
injury, were examined; and the neointimal area, med-
ial area, and neointima/media (NI/M) ratio were
calculated.
Apoptosis assay in the intima
Seven days after the carotid artery injury, the carotid
arteries were snap-frozen in liquid nitrogen in OCT-
embedding medium and stored at −80 °C. Six cross-
sections (5-μm thick), cut from the approximate mid-
dle portion of the artery, were used for the detection
of intimal apoptotic cells by immunofluorescence for
terminal deoxynucleotidyl transferase dUTP nick-end
labeling (TUNEL) by using the in situ Cell Death De-
tection Kit (Roche), according to the manufacturer’s
instructions, and then SmαA staining of VSMCs,
DAPI staining of the nuclei of cells was performed.
After the fluorescence staining, the numbers of
TUNEL-positive and-negative nuclei were counted in
five different high-power fields (HPFs) in each section
under the LSCM. Apoptosis activity was expressed in
terms of TUNEL-labeling index, calculated by dividing
the positively labeled cells by the total cell number.
VSMCs and EPCs co-culture
For the settlement of the VSMC/EPC system, VSMCs
were seeded on Transwell filters (4 μm pores or
8 μm pores, Corning Costar, USA). A total of 2.5 ×
105 EPCs were cultured and were transfected in a
separate well, on the lower chamber of the system.
After both types of cells reached confluency, the
inserts with VSMCs were added to the wells where
EPCs were cultured (resulting). Three groups of cells
were VSMCs and EPCs co-cultured (Fig. 1): (1) con-
trol group: no cells were cultured on the lower
chamber of the system; (2) pEGFP-N2 group : EPCs
with the plasmid pEGFP-N2 transfection were cul-
tured on the lower chamber of the system; (3)
pEGFP-N2-PDGFR-β group : EPCs with the plasmid
pEGFP-N2-PDGFR-β transfection were cultured on
the lower chamber of the system.
VSMC migration assay
The co-culture migration assay was examined using
the VSMC/EPC system containing 8 μm polycarbon-
ate filter inserts in 24-well plates. Three groups of
cells were filled in various concentrations (0, 20, 40,
60, or 80 ng/mL) PDGF-BB respectively. After 12 h
in culture, VSMCs on the bottom of the Transwell
membrane were fixed with 4 % PFA at 37 °C for
20 min and stained with 1 % crystal violet at 37 °C
for 5 min. The number of migrating cells on the bot-
tom of the Transwell in 5 randomly HPFs (×200) was
counted manually. Results were representative of
three independent experiments.
VSMC apoptosis assay
The co-culture apoptosis assay was identified by im-
munofluorescence for TUNEL by using the in situ
Cell Death Detection Kit (Roche, USA), according to
the manufacturer’s instructions. Briefly, the VSMC/
EPC system containing 4 μm polycarbonate filter in-
serts in 24-well plates were used. Three groups of
cells were treated with various concentrations (0, 20,
40, 60, or 80 ng/mL) PDGF-BB in DMEM/F-12 with
1 % FCS (apoptotic condition) for 72 h. VSMCs were
fixed in 4 % PFA for 20 min and then treated with
permeabilization solution (0.2 % Triton X-100 solu-
tion in PBS) for 5 min at room temperature. Labeling
reactions were performed with 100 μL of reaction
buffer for 60 min at 37 °C in a in the dark. DAPI
staining of the nuclei of VSMCs was performed. After
the fluorescence staining, the numbers of TUNEL-
positive and-negative nuclei were counted in five
HPFs (×200). Results were representative of three in-
dependent experiments. The TUNEL-labeling index
was counted manually.
Statistical analysis
Data from independent experiments were expressed as
mean ± standard deviation (SD). Statistical analyses were
Fig. 1 Illustration of the transwell co-culture system. The transwell
consists of two chambers separated by a porous membrane. The
VSMCs were placed on the membrane of the upper chamber while
no cells, EPCs with the plasmid pEGFP-N2 transfection, or EPCs with
the plasmid pEGFP-N2-PDGFR-β transfection were placed on the
bottom of the lower chamber, respectively
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performed with the SPSS 13.0 software (SPSS Inc,
Chicago, USA). Comparisons between the groups were
performed by two-tailed Student’s t-test or analysis of
variance (ANOVA). Comparisons between multiple
groups were tested by Multi-Way ANOVA. P < 0.05 was
considered statistically significant.
Results
Overexpression of PDGFR-β in transfected EPCs
EPCs were transfected with either pEGFP-N2 or pEGFP-
N2-PDGFR-β. After 10 days of transfection, the mRNA
level of PDGFR-β in the pEGFP-N2-PDGFR-β group
(0.38 ± 0.02) was significantly increased as compared to
that in the non-transfected group (0.24 ± 0.03, p < 0.05)
or the pEGFP-N2 group (0.23 ± 0.04, p < 0.05), as deter-
mined by semi-quantitative RT-PCR (Fig. 2a). Similarly,
significantly increased protein level of PDGFR-β was
also found in the pEGFP-N2-PDGFR-β group (1.30 ±
0.41) compared to that in the non-transfected group
(0.60 ± 0.16, p < 0.05) and the pEGFP-N2 group (0.63 ±
0.26, p < 0.05), as determined by western blotting
(Fig. 2b). Our results showed that this overexpression
was maintained for at least 10 days.
Expression of PDGF-BB after wire-mediated carotid artery
injury in mice
Localization of the PDGF-BB in injured vessels was
investigated by immunofluorescence. PDGF-BB was
rarely observed in uninjured carotids (Fig. 3a), but
observed in the intima of local injured carotids at day
7 (Fig. 3b).
We analyzed the PDGF-BB expression during vascu-
lar injury following wire-mediated carotid artery
injury in mice. As shown in Fig. 3c, the PDGF-BB
mRNA expression was detected at low levels in unin-
jured control arteries (0 h), and started reducing
rapidly at 6 h (3.51-fold). However, the PDGF-BB
mRNA level was significantly enhanced at day 7
(3.80-fold) after the vascular injury, followed by a
gradual decline at day 14 (1.67-fold).
The PDGF-BB protein expression was assessed by
western blotting. The protein level started reducing
rapidly at 6 h (7.80-fold) and 12 h (2.82-fold). How-
ever, the level began increasing gradually at day 2
(2.67-fold), with significant enhancement at day 7
(4.26-fold; Fig. 3d).
Labeled EPCs were observed in injured artery
After 7 days of EPC transplantation, acLDL-DiI-
labeled EPCs were identified as red fluorescence cells
(Fig. 4a, b). Labeled cells were seen lining the lumen
that co-stained for endothelial markers FITC-UEA-1.
No acLDL-DiI-labeled cells were identified in unin-
jured control arteries (data not shown).
Transplantation of EPCs overexpressing PDGFR-β pro-
moted reendothelialization
To investigate whether PDGFR-β overexpression could
accelerate reendothelialization, Evans Blue staining was
performed (Fig. 5a). At day 4, the reendothelialized
area in the pEGFP-N2-PDGFR-β-EPCs transplanted ar-
teries (17.76 ± 3.35 %) was significantly larger than in
the saline control group (8.83 ± 3.16 %, p < 0.01) but
Fig. 2 Overexpression of PDGFR-β in transfected EPCs. At 10 days after transfection, PDGFR-β mRNA level (a) and protein levels (b) in the pEGFP-
N2-PDGFR-β group were significantly higher than those in the control group and pEGFP-N2 group.*P< 0.05 vs. control or #P< 0.05 vs. pEGFP-N2 (n= 3)
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was not significantly larger (P > 0.05) than that in the
pEGFP-N2-EPCs transplanted arteries (16.56 ± 4.46 %;
Fig. 5b). At day 7, the reendothelialized area in the
pEGFP-N2-PDGFR-β-EPCs transplanted arteries (58.55 ±
7.17 %) was significantly larger than that in the pEGFP-
N2-EPCs transplanted arteries (48.62 ± 4.55 %; p < 0.05;
Fig. 5b) and that in the saline control group (29.15 ±
7.07 %, p < 0.01). At day 14, the reendothelialized area
in the pEGFP-N2-PDGFR-β-EPCs transplanted arteries
(76.41 ± 10.16 %) was significantly larger than that in
the pEGFP-N2-EPCs transplanted arteries (53.00 ±
7.98 %, p < 0.01) and that in the saline control group
(34.6 ± 6.06 %, p < 0.01). These results demonstrate
that reendothelialization of injured carotid arteries is
promoted by EPC transplantation and further en-
hanced by transplantation with EPCs overexpressing
PDGFR-β at days 7 and 14 after wire-mediated
carotid artery injury.
Fig. 3 Comparison of expression of PDGF-BB in normal and vascular injured mice. Arrows indicate immunofluorescence staining for PDGF-BB
(green) in normal (a) and wire-mediated carotid artery injury mice (b). c Semi-quantitative RT-PCR revealed that PDGF-BB was significantly
enhanced at day 7. d Top: Representative images from western blotting. Bottom: Protein level of PDGF-BB, as assessed by densitometric analysis.
*P < 0.05 vs. 0 h; **P < 0.01 vs. 0 h (n = 3). L, lumen; M, media. Scale bar = 50 μm
Fig. 4 EPCs tracing in vivo. a Labeled pEGFP-N2-EPCs and b pEGFP-N2- PDGFR-β-EPCs were injected into the mice after vascular injury and
attached to the vascular injury site on day 7. Arrows indicate EPCs (n = 5). L, lumen; M, media. Scale bar = 50 μm
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Transplantation of EPCs overexpressing PDGFR-β attenu-
ated neointima formation
The effect of transplantation of EPCs overexpressing
PDGFR-β on neointima formation was evaluated by
HE staining at 14 days after the carotid injury. At day
14, a significant decrease (P < 0.05) in NI/M ratio was
noted in the pEGFP-N2-PDGFR-β-EPCs group (0.29
± 0.07) as compared with that in the pEGFP-N2-EPCs
group (0.43 ± 0.08; Fig. 6a, b) and in the saline con-
trol group (0.73 ± 0.13, p < 0.01). Our results indicate
that the transplantation of EPCs overexpressing
PDGFR-β can inhibit neointima formation in the early
phase after carotid artery injury.
Transplantation of EPCs overexpressing PDGFR-β in-
creased intima cells apoptosis
We next examined the effects of transplantation of EPCs
overexpressing PDGFR-β on intima cells apoptosis/ne-
crosis by TUNEL staining (Fig. 7a, b and c). After 7 days
of the carotid injury, the TUNEL-labeling index was sig-
nificantly greater in the pEGFP-N2-PDGFR-β-EPCs
group (36.45 ± 5.83) than in the pEGFP-N2-EPCs group
(24.45 ± 6.08, p < 0.01, Fig. 7d), indicating increased
intima cell apoptosis was associated with PDGFR-β
overexpression.
Effects of EPCs overexpressing PDGFR-β on PDGF-BB-
induced VSMC migration
To examine the effects of PDGF-BB-induced VSMCs,
co-culture Transwell system was used. The main
effect of concentration (F = 271.088, P < 0.01) and
group (F = 335.35, P < 0.01), as well as their inter-
action (F = 34.699, P < 0.01), were all significant. The
maximum migration induced by recombinant PDGF-
BB occurred at 20 ng/mL in the control group and
pEGFP-N2-PDGFR-β groups and at 60 ng/mL in the
pEGFP-N2 group (Fig. 8b). Interestingly, in the pEGFP-
N2-PDGFR-β group, VSMCs migration decreased
significantly with increase in PDGF-BB concentration
(P < 0.01) (Fig. 8a, b), indicating that PDGF-BB-induced
VSMCs migration is attenuated by EPCs overexpressing
PDGFR-β.
Effects of EPCs overexpressing PDGFR-β on PDGF-BB
treatments reduced VSMCs apoptosis
VSMCs apoptosis plays an important role in vascular
remodeling. We then used the in situ Cell Death
Detection Kit to examine the effects of PDGF-BB
treatments reduced VSMCs apoptosis. The main
effects of concentration (F = 17.798, P < 0.01) and
group (F = 74.428, P < 0.01), as well as their inter-
action (F = 10.376, P < 0.01), were all significant. The
minimum TUNEL-labeling index was at 20 ng/mL
PDGF-BB in the control group and at 80 ng/mL
PDGF-BB in the pEGFP-N2 group respectively
(Fig. 9a). In contrast, in the pEGFP-N2-PDGFR-β
group, TUNEL-labeling index remained unchanged
under different concentrations of PDGF-BB (P > 0.05)
(Fig. 9b), indicating that PDGF-BB treatments reduced
VSMCs apoptosis is attenuated by EPCs overexpress-
ing PDGFR-β.
Discussion
In this study, we found that transplantation of EPCs
overexpressing PDGFR-β significantly promoted reendo-
thelialization in the early phase after carotid artery injury
in mice. Additionally, EPCs overexpressing PDGFR-β
inhibited neointima formation via increasing apoptosis
and suppressing proliferation of VSMCs. The cause of
limited neointima formation might be that homed EPCs
overexpressing PDGFR-β can compete for the locally
produced PDGF-BB which is a result of injured arteries
with the VSMCs, therefore inhibiting the local VSMC
migration, proliferation, antiapoptotic function, and re-
duced neointima formation. This assumption then con-
firmed by our experimental results in vitro. This study
first reported that transplantation of genetically modified
Fig. 5 Reendothelialization of injured carotid arteries is promoted by
EPC transplantation and further enhanced by transplantation with EPCs
overexpressing PDGFR-β. a Representative images of reendothelialization
at days 4, 7, and 14 after wire-mediated carotid artery injury in the saline
control, pEGFP-N2, and pEGFP-N2-PDGFR-β groups. b Quantification of
Evans blue staining showed that PDGFR-β overexpression accelerated
reendothelialization at days 7 and 14 after wire-mediated carotid artery
injury, while no difference was observed at day 4. ** P< 0.01 vs. saline
control group; #P< 0.05 vs. pEGFP-N2 group; ##P< 0.01 vs. pEGFP-N2
group (n= 8 per study group). Scale bar = 1 mm
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EPC can have a combined effect of both amplifying the
reendothelialization capacity of EPCs and inhibiting neo-
intima formation so as to facilitate better inhibition of
adverse remodeling after vascular injury.
EPCs can differentiate into mature ECs in vivo and
therefore play an important role in vascular endothelial re-
pair and angiogenesis in the ischemic tissues [17, 20–23].
The number and biological function of the body’s circu-
lating EPCs largely reflect the ability of vascular repair
and microvascular reconstruction of the ischemic tis-
sues [6, 8, 24, 25]. In certain diseases such as diabetes,
coronary heart disease, and chronic renal failure, the
number and/or biological function of the circulating
EPCs decreases significantly, causing and/or facilitating
Fig. 7 Transplantation of EPCs overexpressing PDGFR-β induces apoptosis of medial cells (VSMCs). Fluorescent TUNEL staining in injured arteries
of the a saline control group, b pEGFP-N2-EPCs group, and c pEGFP-N2-PDGFR-β-EPCs group. Arrows indicate TUNEL-positive cells (green). Red: VSMCs
stained with SmαA; Blue: nuclei stained with DAPI. d TUNEL-labeling index. **P< 0.01 vs. saline control group; ##P< 0.01 vs. pEGFP-N2-EPCs group (n= 5). L,
lumen; M, media. Scale bar = 50 μm
Fig. 6 Transplantation of EPCs overexpressing PDGFR-β inhibited neointima formation at day 14 after carotid artery injury. a Representative
photos of carotid artery were stained with HE. b Neointima/media ratios in the injured vessels of the saline-treated, pEGFP-N2-EPCs-transplanted,
and pEGFP-N2-PDGFR-β-EPCs-transplanted groups. **P < 0.01 vs. saline control group; #P < 0.05 vs.pEGFP-N2-EPCs group (n = 12 per study group).
L, lumen; M, media; NI, neointima. Scale bar = 50 μm
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Fig. 9 Effects of PDGF-BB treatments reduced VSMC apoptosis. a Representative images from VSMCs apoptosis when recombinant PDGF-BB
occurred at 80 ng/mL. Arrows indicate TUNEL-positive cells (green). b VSMC apoptosis was examined by using the in situ Cell Death Detection
Kit. ** P < 0.01 vs. Control cells under 0 ng/mL PDGF-BB stimulation. ##P < 0.01 vs. pEGFP-N2 cells under 0 ng/mL PDGF-BB stimulation.
Scale bar = 100 μm
Fig. 8 Effects of PDGF-BB induced VSMC migration. a Representative images from VSMCs migration by recombinant PDGF-BB occurred at 60 ng/
mL. b VSMC migration was examined by the co-culture migration assay.&& P < 0.01 vs. pEGFP-N2-PDGFR-β cells under 0 ng/mL PDGF-BB stimulation.
Scale bar = 100 μm
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the occurrence and development of these diseases [6, 8,
24–26]. Even under the normal physiological condition,
in case of acute vascular injury or acute tissue ischemia
(e.g., vascular endothelial damage due to a surgery), short-
time blocking of the blood flow to organs, and shock lead-
ing to systemic perfusion, the number of circulating EPCs
in the body are insufficient for the repair of the damaged
vascular endothelium, for remodeling of the microvascular
network, and for angiogenesis [17, 21, 27–29].
Previous studies have confirmed that EPC mobilization
or transplantation to increase the number of circulating
EPCs can promote the repair of damaged vascular endo-
thelium [17, 21, 22, 30–36]. Transplantation of EPCs,
whose biological functions have been improved by gen-
etic modification or cytokine induction, could further
enhance the repair of damaged blood vessels, as ob-
served in some previous studies [37, 38]. In addition, a
few studies reported that applying the receptor–ligand
interaction mechanism to promote directional chemo-
taxis of EPCs could increase the number of EPCs hom-
ing to the damaged blood vessels [16, 38–40]. Both these
approaches, acting on a single link, can achieve a certain
effect, but not the desired effect. Presently, the homing,
proliferation, and differentiation of circulating EPCs as
well as the interaction of these cells with the surround-
ing tissue cells remain to be investigated.
Recent data have shown that remote ischaemic pre-
conditioning reduced the incidence of periprocedural
myocardial infarction following PCI [41]. Vascular inter-
ventional therapy as well as several other factors such as
blood flow stress can lead to vascular intima damage,
which can result in adhesion and aggregation of a large
number of platelets in the intimal lesion. The adhesion
of platelets releases a large amount of PDGF. Mean-
while, vascular intimal injury induces transformation of
local VSMCs from contractile cells to secretory cells,
leading to synthesis and secretion of a large amount of
PDGF [42, 43]. PDGF exerts biological activity through
the paracrine and/or autocrine glands. The PDGF family,
especially PDGF-BB, is closely involved with the resten-
osis of the target vessels after PCI, atherosclerosis, and
other vascular intimal proliferative diseases. Under
normal physiological conditions, the normal artery
walls have very low PDGF-BB expression level, but the
PDGF-BB expression level in the target vascular tissue
after PCI or in atherosclerotic vascular lesions is
increased [44–46].
The local production and release of PDGF-BB exert its
function in an autocrine and/or paracrine manner on
the local VSMCs after vascular injury. It promotes pro-
liferation, migration, and phenotype transformation of
VSMCs [47]. In addition, it promotes postoperative
restenosis after PCI and the formation of atherosclerosis
plate [14, 48]. A recent study has also shown that PDGF-
BB can induce proliferation, migration, and angiogenesis
of EPCs over-expressing PDGFR- β receptor [16].
PDGF-BB functions mainly by acting on its specific re-
ceptor. PDGFR is a transmembrane glycoprotein posses-
sing protein tyrosine kinase activity composed of two
subunits, alpha and beta. The beta subunit PDGFR-β
plays an important role in the occurrence and develop-
ment of vascular intimal proliferative diseases induced
by PDGF-BB [14, 48]. PDGFR-β-specific receptor
blockers can effectively inhibit neointimal hyperplasia in-
duced by PDGF-BB and reduce the degree of stenosis
after vascular injury [49, 50].
Our result is consistent with previous report that the
local expression and release of PDGF-BB increased dur-
ing the acute period after carotid artery injury in mice
and that this increase was sustained for a long time (ap-
proximately 2 weeks) [51, 52]. After transplantation of
EPCs overexpressing PDGFR-β or EPCs with blank plas-
mid, we found that the number of EPCs homing to the
injured arteries was significantly higher in the PDGFR-β
overexpression group than in the PDGFR-β non-
overexpression group (blank plasmid-transfected EPCs
group). Evans Blue staining revealed that the reendothe-
lialization area of injured carotid arteries was signifi-
cantly higher in the PDGFR-β overexpression group
than in the PDGFR-β non-overexpression group at both
day 7 and day 14 and improved reendothelialization was
more dramatic at day 14 compared to day 7.
Reendothelialization at sites of spontaneous or iatro-
genic disruption has classically been thought to be a result
from the migration and proliferation of ECs from viable
endothelium adjacent to the sites of injury. Circulating
EPCs as optimal candidates in cell-based therapies for vas-
cular diseases has been well documented in contributing
to the maintenance of endothelial integrity, function, and
regeneration of injured endothelium [7–10]. The number,
migratory capacity, and proliferative capacity of circulating
EPCs are the main factors determine their ability to home
to and incorporate into sites of reendothelialization. Our
previous study has shown that a stably high expression of
PDGFR-β of EPCs can be achieved by transfecting EPCs
with pEGFP-N2-PDGFR-β. The stimulus of exogenous
PDGF-BB can significantly enhance the capability of
proliferation, migration, and angiogenesis in EPCs overex-
pressing PDGFR-β in vitro [16]. These could explain why
both the number of EPCs homing to the injured arteries
and the reendothelialization area of injured carotid arter-
ies were significantly higher in the PDGFR-β overexpres-
sion group than in the PDGFR-β non-overexpression
group.
We further asked whether increased reendothelializa-
tion has an impact on neointima formation. We per-
formed HE staining and found the inhibition of
neointima formation at day 14 after arterial injury in the
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PDGFR-β overexpression group. This result suggests
that PDGFR-β mediated reendothelialization is reversely
correlated with neointima formation during vascular re-
generation at the injury site. To seek the cause of de-
creased neointima formation, we further performed
TUNEL staining to evaluate cell apoptosis to analyze in-
hibition of neointimal hyperplasia by transplanted EPCs
overexpressing PDGFR-β after arterial injury. We found
that transplanted EPCs with PDGFR-β overexpression
can promote local VSMCs apoptosis in the injured ca-
rotid artery in mice at day 7 after cell transplantation.
Then, we established the VSMC/EPC co-culture system
in vitro. Our data shown that PDGF-BB-induced VSMC
migration and PDGF-BB treatments VSMC antiapopto-
tic function is attenuated by EPCs overexpressing
PDGFR-β competitively consume the PDGF-BB.
There are some limitations in our paper: First, our ob-
servations are based on a relatively simple animal model
(young and healthy mice), and thus, the study conclusions
may be limited to non-atherosclerotic arteries. Second, we
did not observe the enhancing effects of the endogenous
PDGF-BB, released locally by the injured carotid arteries
in mice, on the recruitment of EPCs over-expressing
PDGFR-β. The above-mentioned limitations would be ad-
dressed in our future studies.
Conclusions
Our present study suggests that the interaction between
the transplanted EPCs overexpressing PDGFR-β and the
PDGF-BB expressed and released locally by the injured
carotid arteries of mice can promote homing of EPCs
overexpressing PDGFR-β to the injured arteries, acceler-
ate reendothelialization of the injured artery, and inhibit
neointimal proliferation of the injured arteries after vas-
cular injury. In addition, overexpression of PDGFR-β in
the recruited EPCs can competitively consume the
PDGF-BB generated locally by the injured arteries, pro-
moting proliferation, migration, and anti-apoptosis of
vascular VSMCs, which in turn can strengthen the in-
hibition of neointimal hyperplasia induced after vascular
injury. Thus, our results suggest that the transplantation
of EPCs overexpressing PDGFR-β can be used as a novel
therapeutic approach for the treatment of vascular injury
diseases.
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